Please login to the form below

Not currently logged in
Email:
Password:

BMS’ Dr Mike Burgees joins Turnstone Biologics

He joins the immuno-oncology group as its president of R&D

Turnstone Biologics, a North American clinical-stage immuno-oncology company, has appointed Dr Mike Burgees as its president of research and development, a role that will see him lead all functions in the R&D organisation, including preclinical and clinical development.

Dr Burgees has over 20 years’ experience in drug development, most recently as senior vice president, cardiovascular, fibrosis and immunoscience at Bristol-Myers Squibb (BMS).

He said: “Turnstone Biologics is uniquely positioned to deliver breakthrough viral-based immunotherapies for patients with cancer.

“I look forward to working closely with Turnstone’s experienced team and founders, who are driven by science and innovation, to bring these breakthrough medicines to patients.”

Prior to his time at BMS, Dr Burgees held several senior leadership positions at Roche, including acting global head of Roche Pharma Research and Early Development (pRED) and senior vice president and global head of oncology research and early development.

Sammy Farah, president and chief executive officer, Turnstone Biologics, said: “Mike is one of the most respected research and development leaders in the pharmaceutical industry, and has successfully led the global development and registration of several anti-cancer medicines.

“Mike’s oncology expertise will be instrumental in advancing the development of our next-generation viral immunotherapies and powerful immuno-oncology R&D capabilities.”

6th December 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics